Teriparatide

The paradox that makes it work. Parathyroid hormone regulates calcium, and chronically raised levels - primary hyperparathyroidism - cause bone loss. Yet a single daily injection increases bone formation. The difference is entirely one of exposure pattern: an intermittent pulse favours osteoblast activity and survival, while continuous elevation tips the balance toward resorption [3][4]. Teriparatide is recombinant human PTH(1-34), the fragment that carries the receptor-binding activity.

The pivotal trial. 1637 postmenopausal women with prior vertebral fractures were randomised to 20 µg, 40 µg or placebo daily. Over a median 21 months, new vertebral fractures occurred in 14% on placebo, 5% on 20 µg and 4% on 40 µg; new non-vertebral fragility fractures occurred in 6% on placebo and about half that on treatment. The 40 µg dose raised bone density more but had similar fracture effects and more side effects [1]. The benefit persisted after withdrawal [5].

Head to head against a bisphosphonate. VERO was the first trial to compare osteoporosis drugs with incident fractures as the primary outcome. 680 patients per arm with severe osteoporosis - at least two moderate or one severe vertebral fracture - received teriparatide or risedronate for 24 months. New vertebral fractures: 5.4% against 12.0%, risk ratio 0.44. Clinical fractures: 4.8% against 9.8%, hazard ratio 0.48. Non-vertebral fragility fractures: 4.0% against 6.1%, which did not reach significance [2].

Where it sits now. Network meta-analyses place teriparatide among the more effective agents, alongside romosozumab, denosumab and abaloparatide [6][7][8][9]. Romosozumab beat it on bone density in patients transitioning from oral bisphosphonates [10]. Combination with denosumab produced larger density gains than either alone [11][12], and abaloparatide is a related PTH-pathway drug with its own fracture trial [13].

Why it is on this page. Teriparatide is a peptide bioregulator in the strict sense - a fragment of a human regulatory hormone, used to direct tissue behaviour. It is also the only compound in this group with a fracture-endpoint randomised trial, a head-to-head superiority result and a licence. It is worth reading alongside the short peptides here as a demonstration of what that evidence looks like.

PTH(1-34) binds the PTH1 receptor on osteoblasts and osteocytes, raising cyclic AMP and activating PKA signalling. The anabolic outcome depends on the time course: a brief daily pulse increases osteoblast number and lifespan and stimulates bone formation before the resorptive response catches up, whereas sustained exposure drives RANKL expression and net resorption [3][4].

This creates an "anabolic window" - a period after starting treatment when formation outpaces resorption - which narrows over months as resorption rises. It is why teriparatide is given for a defined period rather than indefinitely, and why the gains are lost after stopping unless an antiresorptive follows [14].

The short half-life of about an hour is not a limitation to be engineered away; it is the mechanism [3]. This is the opposite of the design philosophy behind most of the peptides on this site, where longer exposure is treated as self-evidently better.

Recombinant human PTH(1-34), produced in E. coli, supplied as a refrigerated multi-dose pen for daily subcutaneous injection. Related agents include abaloparatide, a PTH-related protein analogue [13], and full-length PTH(1-84), which has been used in some markets [4].

Well characterised over two decades of licensed use. Common adverse effects are transient hypercalcaemia, nausea, headache, dizziness and leg cramps. The 40 µg dose in the pivotal trial produced more side effects than 20 µg without better fracture protection, which set the licensed dose [1].

The osteosarcoma question. Teriparatide carried a boxed warning based on osteosarcoma in rats given high doses for most of their lifespan. Long-term surveillance in humans has not borne this out, and the boxed warning has since been removed in major markets, with the treatment-duration limit relaxed. This is worth knowing as a piece of history: a strong rodent signal that did not translate.

The practical limitation is not toxicity but durability. Bone gained during treatment is lost after stopping unless an antiresorptive follows, which is why sequential regimens have their own literature [14]. Fracture protection did persist for a period after withdrawal in the pivotal trial's follow-up [5], but the density does not hold indefinitely.

Contraindications follow from the mechanism: pre-existing hypercalcaemia, severe renal impairment, prior skeletal radiation, and bone metastases or other metabolic bone disease.

The clinically important interactions are with other osteoporosis drugs, and they are not intuitive. Combining teriparatide with denosumab produced greater bone density gains than either alone [11][12] - whereas earlier work with bisphosphonates suggested they could blunt the anabolic response, which is part of why romosozumab outperformed teriparatide in patients transitioning off oral bisphosphonates [10].

Order matters in a way that is now standard practice: anabolic first, antiresorptive after, not the reverse [14]. Digoxin requires care because of the transient rise in calcium.

A note on fracture risk unrelated to the drug: in the VERO trial, psychotropic medications and proton pump inhibitors were examined as fracture risk factors within the trial population [15].